Inforlife Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INFORLIFE, and when can generic versions of INFORLIFE drugs launch?
INFORLIFE has eleven approved drugs.
There are two US patents protecting INFORLIFE drugs.
There is one patent family member on INFORLIFE drugs in one country and fourteen supplementary protection certificates in six countries.
Summary for Inforlife
| International Patents: | 1 |
| US Patents: | 2 |
| Tradenames: | 11 |
| Ingredients: | 10 |
| NDAs: | 11 |
Drugs and US Patents for Inforlife
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inforlife | NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE | nicardipine hydrochloride | INJECTABLE;INTRAVENOUS | 203978-001 | Apr 17, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Inforlife | NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE | nicardipine hydrochloride | INJECTABLE;INTRAVENOUS | 203978-002 | Apr 17, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Inforlife | LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER | levofloxacin | INJECTABLE;INJECTION | 090343-002 | Jul 7, 2011 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| Inforlife | METRONIDAZOLE IN PLASTIC CONTAINER | metronidazole | INJECTABLE;INJECTION | 206191-001 | Feb 25, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Inforlife Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2020217079 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Inforlife Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1429780 | 13C0012 | France | ⤷ Sign Up | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| 0328535 | 96C0021 | Belgium | ⤷ Sign Up | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
| 0206283 | SPC/GB97/085 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606 |
| 0206283 | 98C0041 | Belgium | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
